The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
July 6, 2015
View Complete Issue         Table of Contents 2019 
Eliglustat (Cerdelga) - An Oral Drug for Gaucher Disease (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Eliglustat (Cerdelga) - An Oral Drug for Gaucher Disease (online only)
July 6, 2015 (Issue: 1472)
The FDA has approved eliglustat (Cerdelga – Genzyme), an oral glucosylceramide synthase inhibitor, for treatment of adults with type 1 Gaucher disease. Eliglustat is metabolized primarily by CYP2D6. Because patients who are CYP2D6 ultra-rapid...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Eliglustat (Cerdelga) - An Oral Drug for Gaucher Disease (online only)
Article code: 1472d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.